Section Arrow
ATYR.NASDAQ
- aTyr Pharma Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/01/05 08:53 EST
Pre Market
Last
 0.7423
-0.0168 (-2.21%)
Bid
0.7424
Ask
0.7499
High 0.7499 
Low 0.7316 
Volume 16.89K 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
0.7591 
1-M High
-- 
Volume 
-- 
Bid
0.7424
Ask
0.7499
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
74.38M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.83/-0.77
Enterprise Value
86.41M
Balance Sheet
Book Value Per Share
0.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
235.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 26.8 +0.18 +0.68%
ZVRAZevra Therapeutics-------- 
Pre Market 8.475 +0.135 +1.62%
ZURAZura Bio Limited-------- 
Pre Market 5.69 +0.14 +2.52%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 1.4 +0.03 +2.19%
ZLABZai Lab Limited-------- 
Pre Market 18.01 +0.68 +3.92%
Industry overview quotes are at least 15 minutes delayed
Business Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause tofibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.